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Objective: To assess the utility of 64 MDCT in the diagnosis, staging and follow-up of HB
patients.
Patients & methods: This study included 17 children, 9 males and 8 females with HB from
multiple centers aged 6 months- 3 years. Patients were subjected to complete clinical
examination and laboratory investigations at presentation and during follow-up. Patients
were evaluated, staged and treated according to SIOPEL HB protocols for management.
Imaging evaluation was conducted using abdominal U/S, bone scan and MDCT for chest
and abdomen.
Results: All patients were presented with abdominal mass and elevated AFP level, Jaundice
seen in only 1 patient. On MDCT, 13 patients had single focal lesion, 2 patients had multiple
foci and 2 patients showed diffuse disease. MDCT was more accurate than US in detecting
site, multiplicity, density and lymph nodes (LNs). Regarding tumor staging, MDCT findings
were confirmed surgically. In follow-up of patients MDCT was detected with accuracy
residual or recurrent lesions in 3 cases.
Conclusion: MDCT in children with HB accurately displayed the extent of hepatic involve-
ment by tumor, tumor staging and its proximity to vascular structures that help the sur-
geon to identify the tumor resectability and can be used in follow-up.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by
Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatoblastoma (HB) is the primary hepatic malig-
nancy in children accounting for 0.5–2% of all the solid
tumors in childhood. It is the most common primary hep-atic malignancy of childhood representing 91% of primary
hepatic malignancies in children less than 5 years of age
and the mean age of presentation is 16 months. It affects
boys more than girls [1]. The cornerstone for treatment
includes preoperative chemotherapy and then complete
surgical resection of the tumor, followed by adjuvant
chemotherapy [2]. Preoperative chemotherapy shares to
improve the resectability of the tumor [3].
The probability of cure for hepatoblastoma is related
strictly to the feasibility of achieving a complete mass
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indicated to secure the diagnosis of a liver tumor. Alpha
fetoprotein (AFP) is elevated in most children with hepatic
malignancy [4]. Although AFP is not pathognomonic for a
malignant liver tumor, its level monitoring represents a
valuable marker of the response to the pre-surgical
chemotherapy, evaluation of the excision result and for
the early diagnosis of the hepatoblastoma relapse [5].
Imaging plays a pivotal role in the diagnosis and man-
agement of children with hepatoblastoma [6]. Major
advances in diagnostic imaging, especially enhanced com-
puted tomography permit a preoperative choice of resec-
tion versus transplantation to be achieved in almost all
instances [7]. Multidetector computed tomography
(MDCT) is superior to conventional helical CT and the
reconstruction of images provides much more information
without the degradation of images, and the amount of
radiation exposure can also be reduced [8].
MDCT imaging with its capabilities for multi-planar
image reconstruction has virtually eliminated the need
for conventional arteriography. This new modality ele-
gantly displays the extent of hepatic involvement by tumor
and its proximity to the portal vein, and thus helps to
determine its resectability [9].
The aim of this work was to assess the utility of 64
MDCT in the diagnosis and staging as well as for the
follow-up of hepatoblastoma in pediatric patients.2. Patients and methods
This study included 17 children collected from multiple
centers (Minia Oncology Center, Minia University, South
Valley University, South Egypt Cancer Institute, Assiut
University, Al-Azhar University Assiut branch hospitals)
during the period from January 2013 to January 2016. The
study was approved by the local research ethics committee
of the centers and hospitals and a written informed consent
was obtained from the parents of children to share in the
study. All patients were complaining from abdominal mass
proved by biopsy and histopathology to beHB. The patients’
ages ranged from 6 months to 3 years. All patients were
subjected to thorough history taking and complete clinical
examination including general, chest, cardiac and abdomi-
nal examination. Laboratory Investigations included com-
plete blood count (CBC), liver and renal function tests and
LDH. Serum a-fetoprotein (AFP) level was estimated at pre-
sentation and during follow-up as a marker to monitor
therapy and detect recurrence. All the children were evalu-
ated, staged and treated according to SIOPEL pretreatment
extent of the diseases (PRETEXT) protocols for management
of HB [3]. Surgical resection was the mainstay of treatment
and the prognosis depends on the resectability of the
tumor. Decision regarding resectability was based onMDCT
scan, clinical course and response to neoadjuvant
chemotherapy. Staging based on traditional (EVANS) COG
staging system, with clinical stage was determined by
imaging studies prior to surgery into:
Stage-I: Complete gross resection at diagnosis with
clear margins.Stage-II: Complete gross resection at diagnosis with
microscopic residual disease at the margins of
resection.
Stage-III: Gross total resection with nodal involvement,
tumor spills or complete resection with gross intrahep-
atic disease.
Stage-IV: Metastatic disease (to chest or bone).
We used (SIOPEL1) pretreatment extent of the diseases
(PRETEXT) as a tool to stratify treatment, to define risk
categories and to report outcome.
In tumor resection, not more than 50% of healthy liver
tissues were resected. Patients with diffuse bi-lobar
multi-focal tumor were referred to transplantation center.
Imaging evaluation of our patients was conducted by
abdominal ultrasonography (U/S) and MDCT abdomen.
MDCT chest was included to rule out pulmonary metasta-
sis and bone scan to detect bone metastases.
2.1. Abdominal ultrasonography
The examination was done by high resolution ultra-
sound imaging machine (Logic P5, GE medical systems,
Korea) with convex and sector transducers (4–7 MHz).
Ultrasound was used to localize the mass and estimate
its extent as well as to evaluate its texture. Doppler exam-
ination was used to evaluate the tumoral invasion of the
hepatic veins, inferior vena cava and the portal vein. Preop-
erative liver biopsy was also performed under ultrasound
guidance.
2.2. 64-multidetector computed tomography
Using a 64-row multidetector scanner (Aquilion 64;
Toshiba Medical Systems Corporation, Otawara, Japan),
detailed MDCT for the chest and abdomen was done to
assess resectability and evaluate for the presence of pul-
monary metastases. Postoperative MDCT was performed
to search for tumor residual or recurrence.
2.3. MDCT technique
For CT examination of the abdomen, the intake of oral
contrast medium is essential depending on the child age.
One hour before examination we give the child a diluted
iodinated contrast medium either by mouth or through a
nasogastric tube and another dose should be given while
the child was on the table just prior to the start of exami-
nation. We used a power injector for the administration of
IV contrast material, using a dose of 2.0 ml/kg (concentra-
tion 240 mg I/ml) of water soluble non-ionic contrast agent
in a rate of 5 cc/sec. We used a dedicated pediatric protocol
for CT imaging, in which a combination of decreasing the
peak kilo-voltage and the milliampere-seconds reduces
the radiation dose to pediatric patients [10]. For each
examined region (chest and abdomen) a single-phase
MDCT was obtained following IV administration of con-
trast material. Using an automatic injector and allowing a
60-s delay after start of the injection, the CT images are
obtained. As hepatoblastomas are not as hypervascular as
adult hepatocellular carcinomas, therefore, a dual or
Table 1
Demographic, clinical and laboratory data for studied patients at
presentation.
Parameter Patients (No: 17)
Age (months) Range 6–36 ms
Mean ± SD 14 ± 2.7
Gender Male 9 (52.9%)
Female 8 (47.1%)
Weight (kgs) Range 4–16 kgs
Mean ± SD 9.5 ± 1.9
Height (cms) Range 68–103 cms
Mean ± SD 86.5 ± 7.8
Clinical presentations Abdominal mass 17 (100%)
Fever 3 (17.7%)
Anorexia 5 (29.4%)
Weight loss 6 (35.3%)
Jaundice 1 (5.9%)
AST (IU/L) Range 210–630
Mean ± SD 374 ± 121
ALT (IU/L) Range 380–800
Mean ± SD 529 ± 111
AFP (ng/ml) Range 7000–1,000,000
Mean ± SD 41,100 ± 28,964
LDH (U/L) Range 211–401
Mean ± SD 297 ± 56
Serum creatinine (mg/dl) Range 0.8–3
Mean ± SD 1.65 ± 0.6
Table 2
U/S and MDCT abdomen finding in the studied patients.
Appearance Liver involvement
(Patients No & %)
P value#
U/S MDCT
Location
Rt. lobe 14 (82.35%) 12 (70.58%) 0.002*
Lt. lobe 3 (17.65%) 3 (17.65%)
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mation. Oral sedation was given prior to MDCT examina-
tion with chloral hydrate in a dose of 25 mg/kg. General
anesthesia was used only in 2 irritable patients.
2.4. Image reconstruction
Post-processing was done using multi-planar recon-
struction (MPR) facilities and a 3-D workstation to review
the lesion. A single-phase CT angiography was indicated to
assess lesion vasculature for surgical planning.
Based on the tumor location, the patient is placed in one
of 4 categories: Stage I if 3 adjoining sectors are free; stage
2 if 2 adjoining sectors are free; stage III if one sector is free
and stage IV if no sectors are free of tumor [11].
All the children were treated according to SIOPEL
(PRETEXT) protocol [3] consists of continuous 24-h
intravenous infusion of PLA 80 mg/m2 followed by DO
60 mg/m2 over 48 h (PLADO). After four courses of this
chemotherapy, patients were reassessed. Where possible,
the primary tumor was resected and treatment completed
with two more courses of chemotherapy. AFP levels were
used in follow-up of our patients during the course of ther-
apy and every month in the first year after surgical resec-
tion and if we found any significant increase we repeated
the MDCT abdomen to detect any residual or recurrent of
the tumor.
2.5. Statistical analysis
The data were statistically analyzed using the SPSS soft-
ware package, version 16 (SPSS Inc., Chicago, IL, USA) on a
personal computer. Numerical data were expressed as
range, mean ± SD, Non-numerical data were expressed as
frequencies. Comparative studies were done using chi-
square test (p value < 0.05 was considered significant).Bilobar 0 (0%) 2 (11.77%)
Multiplicity
Single 15 (88.23%) 13 (76.5%) 0.001*
Multiple 2 (11.77%) 2 (11.7%)
Diffuse 0 (0%) 2 (11.7%)
Echogenicity/Density
Homogenous 13 (76.47%) 11 (64.7%) 0.006*
Heterogeneous (with 4 (23.53%) 6 (35.3%)
Hemorrhage and necrosis)
Calcifications
Dense 2 (11.77%) 2 (11.77%) 0.002*
Spotty 3 (17.65%) 0 (0%)
Negative 12 (70.58%) Not seen^
Mass definition
Well defined 11 (64.7%) 12 (70.58%) 0.002*
Semi-defined 6 (35.3%) 3 (17.65%)
Infiltrative 0 (0%) 2 (11.77%)
L Ns
Positive 2 (11.77%) 4 (23.53%) 0.04*
Negative 15 (88.23%) 13 (76.47%)
Vascular involvement
Hepatic and IVC 1 (5.88%) 2 (11.77%) 0.03*
Portal vein thrombosis 2 (11.77%) 2 (11.77%)
# By using chi-square test.
* Significant.
^ Non-contrast study was not performed.3. Results
This study included 17 patients, 9 males (52.9%) and 8
females (47.1%) children with HB. All patients presented
with abdominal mass (100%), AFP level at diagnosis in all
patients with hepatoblastoma showed abnormal elevation,
its level ranged between 7000 and 1,000,000 ng/mL and
marked decline of its level was seen after surgery and
chemotherapy treatment in all patients. Clinical and labo-
ratory data of studied patients at presentation are shown
in Table 1.
On U/S examination the HB lesion was found to be a
solitary mass in 15 patients (88.2%) and only two patients
showed multiple focality, but at the same lobe (Rt. Lobe).
The mass appeared homogenous in 13 patients and
heterogeneous in 4 patients with areas of necrosis or hem-
orrhage. On post contrast MDCT abdomen images, 13
patients had single focal lesion while 2 patients showed
multiple foci in the Rt. lobe and 2 showed diffuse disease
that infiltrates nearly the whole Rt. Hepatic lobe. 11
patients showed homogenous hypodense mass lesion with
uniform contrast enhancement while heterogeneous
hypodense mass lesion with non-uniform pattern of
Fig. 1. Axial contrast-enhanced MDCT images in two different patients showing stage-I hepatoblastoma in (a) 12-month-old female infant involving the left
lobe with ill-defined margins and heterogeneous enhancement and stage-II (b) 9-month-old infant involving the right lobe showing a single hypodense
focal lesion with heterogeneous enhancement and bulges the hepatic surface.
Fig. 2. Axial contrast-enhanced MDCT images in 2-year-old female patient showing stage-II hepatoblastoma involving the left lobe with hypodense
heterogeneous enhancement (a) preoperative and (b) postoperative after doing left lobectomy.
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seen in 2 patients (with dense calcification) and were dif-
ficult to detect in the other patients as we did only a
post-contrast study. Regarding tumor marginal definition,
well defined tumor margin was detected in 12 patients.
Lymph node metastases were noted in 4 patients in the
form of enlarged porta-hepatis and para-aortic lymph node
groups. CT angiography was used to assess involvement of
the vascular structures, IVC and Rt. Hepatic veins were
seen to be invaded in 2 patients and portal vein thrombosis
was detected in 2 patients. Table 2 lists the different find-
ings in both U/S and MDCT abdomen in the studied
patients. Regarding the comparison between the 2 modal-
ities, significant difference was found between them as
MDCT was more accurate in detecting the site, multiplicity,
density, Lymph nodes (LNs) and mass definition.
Tumor staging and assessment for resectability was
done by MDCT abdomen images. Regarding tumor focality,
13 patients were found to have single focal lesion, 10 local-ized in the Rt. Hepatic lobe and 3 at the Lt. Lobe (stage I–II)
and were operated according to lobar and segmental
involvement by lobectomy and/or segmentectomy Figs. 1
and 2. Of the remaining 4 patients, 2 showed multiple foci
with vascular invasion and 1 showed diffuse disease that
infiltrated both hepatic lobes (stage III) and were referred
to transplantation center. Only one patient had stage IV
with pulmonary metastases Figs. 3 and 4. As shown in
Table 3 the MDCT findings regarding tumor staging were
confirmed surgically and the same results were found
(see Fig. 5).
Preoperative neoadjuvant chemotherapy was given to
reduce the tumor size of operable cases. After surgery, all
patients completed the rest of chemotherapy course (total
6 cycles). Five patients had an episodes of neutropenia in
the third cycle treated by antibiotics and 1 patient had ele-
vated serum creatinine by the second cycle; otherwise,
chemotherapy was tolerated without other complications.
During the course of the disease, AFP was found to be
Fig. 3. Axial contrast-enhanced MDCT images in three different patients showing stage-III hepatoblastoma in (a) 20-month-old female patient involving the
right hepatic lobe, showing heterogeneous enhancement. Enlarged para-aortic lymph nodes are also seen (arrow). (b) 8-month-infant showing
predominantly cystic liver mass involving both left and right lobes. Enhancement is limited to the septa and periphery of the tumor. (c) Coronal MDCT
image in a 3-year-old male patient with hepatoblastoma showing infiltration of the right hepatic vein which appears displaced and attenuated (arrow).
Fig. 4. Axial (a) and coronal (b) MDCT images in a 12-month-old infant with multifocal stage-IV hepatoblastoma showing multiple foci scattered
throughout the liver segments.
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Table 3
Comparison of tumor staging by MDCT and the surgical data.
Tumor staging MDCT Surgical data
Stages I–II 13 13
Stages III–IV 4 4
Vascular invasion 4 4
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tumor. Postoperatively follow-up of patients we noticed
elevation of AFP in 4 cases, MDCT abdomen was done to
detect residual or recurrent tumor, it was detected with
accuracy residual lesion as a heterogonous lesion with
irregular wall and faint enhancement in 1 patient and
under-estimates the residual lesion (seen as normal at
the 1st postoperative study) in 1 patient who proved to
have residual tumor at the 2nd follow-upMDCT study after
1 month. An enhancing nodule was noted at the surgical
bed 6 and 11 months after resection respectively in 2
patients who were previously normal at 1st postoperative
CT study.4. Discussion
In children hepatic tumors account for 0.5–2.0% of all
neoplasms and about 1–4% of all solid tumors [12]. The
usefulness of MDCT for the evaluation of pediatric disease
has been reported; however, there have been very few
studies involving pediatric neoplastic diseases, in particu-
lar liver tumors [13]. The goal of treatment of hepatoblas-
toma is to remove the tumor completely [14]. Imaging is
crucial in the assessment of children with HB at the time
of diagnosis and during the preoperative period [15].
Regarding male predominance that has been pointed
out in the report of Tsai et al. [12] and in our study dis-
closed a similar result as we found that 9 males and 8
females were affected.Fig. 5. Six-months infant: (a) Axial enhanced MDCT image shows a well-define
(arrow). (b) On sagittal image a non-enhanced PV is also seen denoting its thromMany studies reported the AFP as a useful laboratory
marker for HB as its level is almost always elevated
[2–16]. Metastatic or extensive tumors may have extre-
mely high serum AFP levels (>1,000,000 ng/mL) [1,17].
Patients with AFP levels that have failed to decrease are a
poor prognostic indicator [18].
In our work all patients with HB showed abnormal ele-
vation of AFP level at diagnosis, and marked decline of its
level was seen after surgery and chemotherapy treatment.
Serum AFP levels were used in follow-up to monitor ther-
apy and detect recurrence.
US is useful as a preliminary imaging study and usually
determines the tumor’s organ of origin. US can be per-
formed quickly and does not involve ionizing radiation
[19]. In this study U/S abdomen was done to all patients,
sonography can be valuable in detecting uninvolved hep-
atic veins that are displaced by the tumor, and it also can
detect early tumor invasion of the portal venous system
[7]. The presence of high-velocity Doppler signals within
a mass and invasion of the portal vein strongly supports
the diagnosis of malignant neoplasm [20]. A spoke-wheel
appearance with areas of alternating echogenicity may be
seen at antenatal imaging [21]. Intra-lesional calcifications
easily are seen as areas of shadowing [22].
Kinoshita [8] & Frush [23] stated that in many institu-
tions for preoperative evaluation of liver tumors we should
do MDCT examination and CT angiography. But, there are
many hazards from the repeated CT scans that are neces-
sary to evaluate the efficacy of the preoperative
chemotherapy due to the accumulative effect of radiation.
On the other hand, general anesthesia is necessary for con-
ventional angiography and it is an invasive procedure for
infants. MDCT rapidly provides images than does conven-
tional CT, which simplifies the process of sedation, and
MDCT gives high quality images and reduces the time
and dose of radiation exposure [13]. MDCT also can clearly
study the precise vascular anatomy and is better to diag-
nose, preoperatively evaluate, and follow up HB [24].d faintly enhanced lesion within right lobe and PV thrombosis is noted
bosis (long thin arrows).
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non-contrast and multi-phased post contrast 64MDCT
from this work as it doesn’t add to the diagnosis informa-
tion. This is in agreement with Chung et al, [25] who rec-
ommended in imaging children, the risks of radiation
exposure and sedation must be weighted. In our experi-
ence HB is not as hypervascular as adult hepatocellular
carcinomas. Therefore, a dual or triple-phase spiral CT will
not provide any additional information.
In our study, post contrast MDCT abdomen revealed
that 13 patients had single focal lesion while 2 patients
showed multiple foci in the Rt. lobe and 2 showed diffuse
disease that infiltrates nearly the whole Rt. hepatic lobe
while 2 patients had diffuse lesions. This was coincidence
with Das et al. [26] who stated that HB usually appears
as a solitary lesion. HB lesion arises from the right lobe
in 12 out of our 17 patients which come in concordance
with Shih et al, [27] who stated that HB arises from the
right lobe more frequently. The left lobe is supplied with
oxygenated blood entirely from the umbilical vein,
whereas the right lobe is supplied with portal vein blood
containing lower oxygen saturation. In our study, the mass
showed well defined tumor margin in 12 patients and the
walls appeared to be semi-defined in 3 patients while 2
patients showed poor wall definition with infiltrating mar-
gins. As regards the vascular invasion, it was documented
with confidence in 2 patients with IVC and Rt. Hepatic
veins invasion and portal vein thrombosis was detected
in 2 patients, the remaining 13 patients had no vascular
invasion. In this point, we coincide with Kinoshit [13],
who observed that if transarterial chemoembolization
(TACE) is not necessary, the MDCT reconstruction images
are considered to provide a sufficient evaluation of the ves-
sels and give accurate image to the precise vascular anat-
omy [24]. However, in HB MDCT angiography is needed
to evaluate malignant neovascularization, stretching of
vessels, pooling of contrast media and invasion or encase-
ment of branches of portal vein or hepatic artery [26].
In our study, we found 11 lesions from 17 lesion are
hypodense with slight homogenous enhancement but
lower than adjacent healthy liver parenchyma while only
6 lesions had inhomogeneous enhancement. HB is usually
seen as a well-defined mass in CT images, which is usually
hypoattenuating compared to surrounding liver. Fre-
quently there are areas of necrosis and hemorrhage. CT is
also able to evaluate nodal enlargement [28]. Regarding
calcification we found calcification only in 2/17 lesions so
we disagree with other studies [28,29], that stated dense
calcification seen in approximately 40% of cases. Also, in
contrary to our results Çeçen et al. [30], concluded, the
liver lesion was heavily calcified, which appeared as a very
dense mass on unenhanced CT examination. Calcifications
were difficult to detect in our patients as we did only a
post-contrast study which were intended to reduce radia-
tion dose. Regarding hepatoblastoma staging we got the
same results when Compared MDCT to the surgical data
and the complete surgical excision represents the essence
of the HB treatment [31].
Postoperatively, MDCT abdomen detected with accu-
racy the residual lesion in 1 patient and under-estimate
the residual lesion (reported as normal at the early postop-erative study) in 1 patient who proved to have residual
tumor at the 2nd follow-up CT, after 1 month period. An
enhancing nodule was noted at the surgical bed 6 and
11 months after resection respectively in 2 patients who
were previously normal at the early postoperative MDCT
evaluation. False-negative images for tumor recurrence
may be observed following tumor resection and CT may
fail to recognize neoplasm until a sufficient volume of
lesion is present. In these patients, recurrent tumor usually
becomes evident on follow-up imaging [19].5. Conclusion
MDCT in children with HB accurately displays the
extent of hepatic involvement by tumor, tumor staging
and its proximity to the vascular structures that could help
the surgeon and can be used in follow-up. It can be per-
formed quickly, easily, and usually with only light seda-
tion. MDCT with its multi-planar image devises a
comparative safe surgical strategy. We recommend using
MDCT scan in diagnosis, staging and follow-up of HB.Author contribution
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